SDIC Fund Leads $66M Round In Chinese Respiratory Drug Developer CF PharmaTech

SDIC Fund Management Company Ltd., a private equity firm majority owned by China’s State Development & Investment Corporation (SDIC), has led a RMB440 million (US$66 million) series D round in CF PharmaTech Inc., a Chinese company developing drugs to treat respiratory diseases.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets